Lilly to post 2008 loss on ImClone costs
INDIANAPOLIS - Eli Lilly and Co. said Thursday its $6.5 billion ImClone acquisition will wipe out its 2008 profit and dent next year's earnings as well.
Nations:U.S. Source:(AP)
2008-12-11
Improving the Use of Drugs Through Genes
Getting a personal gene analysis right now may not tell you much that's useful to your health. But that doesn't mean the technology can't improve medical care and save lives. One of the most promising uses for information is fine-tuning how drugs are prescribed. That's because some genetic variations that turn up in gene testing affect how people respond to pharmaceutical products. My liver enzymes might be speed demons when it comes to clearing drugs from my blood, while yours work far more slowly. So I'll need a higher dose of the drug to get the same medical effect. To take an extreme case, one-third of people with a particular gene die when given a certain AIDS drug. Yet in patients without the genetic variation, the drug works great. So doctors must test for the gene before prescribing the drug.
Nations:U.S. Source:(BusinessWeek)
2008-10-27
Eli Lilly agrees to buy ImClone for over $6B
NEW YORK - The drugmaker Eli Lilly & Co. said Monday it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand its pipeline of cancer treatments.
Nations:U.S. People:Carl Icahn Source:(AP)
2008-10-06
Blue chips rise; S&P logs best week since '03
U.S. blue chips inched up on Friday, capping a rally in which the S&P 500 logged its biggest weekly gain since 2003 on speculation that the Federal Reserve's next move will be an interest rate cut.
Activities:U.S. Markets
2007-03-23
Amgen shares fall on drug setbacks
Amgen Inc. (Nasdaq:AMGN) shares fell 5 percent on Friday after two of the company's medicines posted disappointing data, including a higher death rate for some cancer patients on its anemia treatment Aranesp.
2007-01-26
| 
